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The expression of estrogen receptor is the key in most breast cancers (BC) and
binding of estrogen receptor to the genome correlates to Forkhead protein
(FOXA1) expression. We herein assessed the correlation between the cancer stem
cell (CSC) population and FOXA1 expression in luminal BC. We established lumi-
nal BC cells derived from metastatic pleural effusion and analyzed the potency of
CSC and related factors with established luminal BC cell lines. We also confirmed
that mammosphere cultures have an increased aldehyde dehydrogenase-positive
population, which is one of the CSC markers, compared with adherent culture
cells. Using a quantitative PCR analysis, we found that mammosphere forming
cells showed a higher expression of FOXA1 and stemness-related genes
compared with adherent culture cells. Furthermore, the growth activity and col-
ony-forming activity of 4-hydroxytamoxifen-treated BC cells were inhibited in a
mammosphere assay. Interestingly, 4-hydroxytamoxifen-resistant cells had signifi-
cantly increased FOXA1 gene expression levels. Finally, we established short hair-
pin RNA of FOXA1 (shFOXA1) MCF-7 cells and investigated the relationship
between self-renewal potential and FOXA1 expression. As a result, we found no
significant difference in the number of mammospheres but decreased colony for-
mation in shFOXA1 MCF-7 cells compared with control. These results suggest that
the expression of FOXA1 appears to be involved in the proliferation of immature
BC cells rather than the induction of stemness-related genes and self-renewal
potency of CSCs.
B reast cancer (BC) treatment has progressed in recentdecades. Many previous clinical studies clarified that
pathological characteristics, such as estrogen receptor (ER),
progesterone receptor (PgR), human epidermal growth factor
receptor 2 (HER2), and Ki-67 expression, correlate with the
gene expression profile, such as PAM50,(1,2) prognosis, and
treatment effects. Therefore, we can clinically divide BC
into five types according to these pathological characteristics
in consideration of the therapeutic plan: luminal A, luminal
B, luminal-HER2, HER2-enrich, and triple negative type.(3)
For luminal A and B, which are categorized as ER-positive
BC, endocrine therapy can be used with chemotherapy
treatment.
It is known that ER-positive BC constitute approximately
70% of all BC, and it shows a good prognosis.(4–6) However,
it has been reported that ER-positive and HER2-negative BC
patients with low Ki-67 proliferation, so-called luminal A type,
can lead to late recurrence compared to other BC subtypes,
possibly due to the presence of dormant tumor cells.(7) The
BC markers of late recurrence(8–10) or commercialized prog-
nostic prediction systems such as Oncotype DX(11) and Mam-
maPrint(12) have been established. However, the BC cell
mechanism of late recurrence is still poorly understood.
Cancer stem cells (CSCs) have been isolated and character-
ized to have high potential for tumor growth, self-renewal,
multidifferentiation, high metastatic ability, and drug resis-
tance.(13–18) Interestingly, there are many similar biological
characteristics between dormant cells and CSCs, especially in
terms of therapy resistance and cell signals that regulate self-
renewal and the quiescent state of CSCs.(19–21) Therefore, it is
speculated that CSCs might contribute to late recurrence with
dormant cells,(22) and we hypothesized that some part of CSCs
would be involved in the late recurrence of luminal type A in
this study.
Al-Hajj et al.(13) reported that the CD44+ ⁄CD24/low popula-
tion of BC cells showed higher tumor initiating potential than
other populations. In addition, Ginestier et al.(23) reported that
aldehyde dehydrogenase (ALDH) 1 is a good marker for both
stem cells of normal mammary cells and BC cells. Moreover,
it has been reported that the expression of these CSC markers
correlate with a clinically poor outcome.(23–26) These markers
were positively expressed in triple negative BC cells as well
as in normal mammary stem ⁄progenitor cells. Additionally,
most of the previous reports showed that they were ER-nega-
tive.(27) Regarding CSCs of the luminal type of BC, Sun
et al.(28) reported that estrogen promotes stemness and
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invasiveness through Gli1 activation, however, the mechanisms
that maintain CSCs in luminal BC remains obscure.
Forkhead protein (FOXA1) is the downstream target of
GATA binding protein 3 and maintains ER sensitivity.(29)
FOXA1 directly binds to the estrogen receptor 1 promoter and
activates ER mRNA expression.(30) Moreover, it is known that
FOXA1 binds to chromatin DNA and modulates ER activ-
ity.(31,32) Conversely, it has been reported that FOXA1 acti-
vates p27 transcription and works as a growth repressor.(33)
Until now, the correlation between FOXA1 and CSCs through
ER has not yet been determined. According to tissue samples,
Horimoto et al.(34) clarified that those metastatic breast cancer
patients whose tissue highly expressed FOXA1 took a long
time to relapse compared to low FOXA1 patients, indicating
that FOXA1 might be related to late recurrence. Taken
together, the tendency for luminal A type BC and FOXA1-
enriched BC to cause late recurrence, and the similarity
between CSCs and dormant cells, it may be hypothesized that
FOXA1 expression, especially in CSCs, causes late recurrence
and provides a poor prognosis for patients.
In this study, we investigated the mechanisms of initiation
of luminal breast CSCs to understand how those CSCs influ-
ence BC late recurrence. First, we analyzed the potency of
CSCs and related factors by a mammosphere assay compared
to adherent culture BC cells. Under mammosphere culture, we
found that CSC populations of luminal BC have increased
FOXA1 expression compared with the control population. The
FOXA1 knockdown study showed that FOXA1 is involved in
the proliferation of immature BC cells rather than the induc-
tion of stemness-related genes and self-renewal potency of
CSCs. Our findings may therefore help to establish a novel
strategy to treat luminal BC and its late recurrence.
Materials and Methods
Cell lines. The MCF-7 and MDA-MB-231 human breast can-
cer cell lines were purchased from RIKEN BioResource Center
(Ibaraki, Japan). HCC1500 human breast cancer cells were
purchased from ATCC (Manassas, VA, USA). All cells were
cultured in DMEM high glucose medium (Gibco; Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with
10% FBS (Thermo Fisher Scientific), L-glutamine, MEM–non-
essential amino acid solution, and penicillin ⁄ streptomycin.
Cells were maintained in a humidified incubator at 37°C at an
atmospheric pressure of 5% (v ⁄v) CO2 ⁄ air.
Patient sample and established cell lines. A surgical breast
cancer tissue sample and metastatic pleural effusion from a
breast cancer patient (79 years of age, ER [+], PgR [+], HER2
[0]), under aromatase inhibitor treatment, were harvested fol-
lowing the approval of the ethics committee at University of
Tsukuba (Tsukuba, Japan). The pleural effusion was treated
with RosetteSep Human CD45 Depletion Cocktail (Stemcell
Technologies, Vancouver, BC, Canada) according to the manu-
facturer’s instructions. The cells were then laid onto a density
gradient buffer (HISTOPAQUE-1083; Sigma-Aldrich, St.
Louis, MO, USA) and centrifuged at 460g for 20 min at room
temperature. The mononuclear cells were collected and plated
at the density of 2 9 105–2 9 106 cells ⁄mL in a 25-cm2 cul-
ture flask (Sumitomo Bakelite, Osaka, Japan) and maintained
at 37°C in 5% CO2.
Establishment of shFOXA1 cells. We purchased OmicsLink
shRNA Expression Clone targeted to FOXA1 and scrambled
control gene (GeneCopoeia, Rockville, MD, USA). The
shRNA clones were transfected into HEK293T cells using the
Lenti-Pac HIV Expression Packaging Kit (GeneCopoeia) and
pseudo-viral particles were harvested.
These particles were then transduced into target cells and
selected with puromycin. The effect of shRNA of FOXA1 was
assessed by an immunoblot analysis.
Flow cytometry. To characterize and analyze BC cells, flow
cytometry was used (MoFlo XDP; Beckman Coulter, Tokyo,
Japan) with CD44-FITC antibody (BD Biosciences, San Jose,
CA, USA) and CD24-PE antibody (BioLegend, San Diego,
CA, USA) as previously reported.(31) For ALDH activity, an
ALDEFLUOR kit (Stemcell Technologies) was used according
to the manufacturer’s instructions.
Mammosphere formation assay. Mammosphere culture was
carried out using MammoCult medium (Stemcell Technolo-
gies), hydrocortisone, penicillin ⁄ streptomycin, and heparin
according to the manufacturer’s instructions. Approximately
1 9 104 cells were plated onto 35-mm petri dishes (Sumitomo
Bakelite), and the number of mammospheres over 100-lm
diameter was counted under a microscope. To analyze the
effects of 4-hydroxytamoxifen (4-OHT; Sigma-Aldrich, Tokyo,
Japan) on the mammospheres derived from BC cells, a concen-
tration of 1 lM 4-OHT ⁄ dish was used.
Colony formation assay. The cells were seeded in triplicate at
100 cells ⁄6-well plate (Sumitomo Bakelite) in complete med-
ium. After 2 weeks, the cells were fixed and stained with 0.5%
w ⁄v crystal violet in methanol. Visible colonies were scored
by macroscopic observation.
Quantitative RT-PCR. Total RNA was prepared from samples
using extraction reagent (Sepasol-RNA I Super G; Nacalai Tes-
que, Kyoto, Japan), and cDNA was synthesized by reverse tran-
scription using the ReverTra Plus kit (Toyobo, Osaka, Japan).
The expression levels of target genes were analyzed using a
7500 Fast Real-Time PCR machine (Applied Biosystems, Foster
City, CA, USA) with Thunderbird SYBR qPCR Mix (Toyobo).
Experiments were carried out in triplicate and data were calcu-
lated using the DCt method. The sequences of the primers used
for quantitative RT-PCR are shown in Table 1.
Western blot analysis. Whole cell extract was prepared using
RIPA buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium deoxy-
cholate, 1% NP-40, and 0.1% SDS). Samples were elec-
trophoresed on a 7.5% SDS–polyacrylamide gel and transferred
onto PVDF membranes (Merck Millipore, Darmstadt, Germany).
After blocking with 5% skim milk ⁄TBST buffer, the membranes
were incubated with anti-FOXA1 antibody (clone2F83, dilution
1:1000; Abcam, Tokyo, Japan) or anti-actin antibody as control
(clone C-11, dilution 1:2000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). After washing, the membranes were incubated
with HRP-conjugated secondary antibodies, and positive signals
Table 1. Polymerase chain reaction primers used in this study
Human Oct4 Sense: 50-CTGGGGGTTCTATTTGGGAAGGTA-30
Antisense: 50-CTGCAGGAACAGATTCTCCAGGTT-30
Human Nanog Sense: 50-ACAGAAATACCTCAGCCTCCAGCA-30
Antisense: 50-CTCCAGGTTGAATTGTTCCAGGTC-30
Human Sox2 Sense: 50- GAGTGGAAACTTTTGTCGGAGACG-30
Antisense: 50-CCGGTATTTATAATCCGGGTGCTC-30
Human ESR1 Sense: 50-ATGTGTAGAGGGCATGGTGGAGAT-30
Antisense: 50-GACTTCAGGGTGCTGGACAGAAAT-30
Human FOXA1 Sense: 50-ACTCGTACATCTCGCTCATCACCA-30
Antisense: 50-CAAGTAGCAGCCGTTCTCGAACAT-30
Human b-actin Sense: 50-CTGGCACCACACCTTCTACAATGA-30
Antisense: 50-TAGCACAGCCTGGATAGCAACGTA-30
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were analyzed by a luminescence imager (Image Quant
LAS4000; GE Healthcare, Little Chalfont, UK) using chemilumi-
nescence reagents (Merck Millipore).
Immunohistochemical staining. The cell pellets were fixed in
10% formalin and 70% ethanol. After fixation, samples were
embedded in paraffin blocks.
Immunohistochemical staining was carried out by the Trans-
lational Research and Resource Core at the University of Tsu-
kuba. Nearly all staining methods, except for HER2, were
based on the autostainer BenchMark ULTRA (Roche, Tokyo,
Japan) protocols; HER2 was stained as recommended by the
supplier. The following antibodies were used: mouse anti-
FOXA1 antibody (clone2F83, dilution 1:2000; Abcam);
Ventana ultraView confirm ER (clone SP1; Roche); Ventana
ultraView confirm PgR (clone 1E2; Roche); Histofine HER2
kit (Nichirei, Tokyo, Japan); cytokeratin (CK) 5 ⁄6 (clone D5
⁄16 B4; Dako, Tokyo, Japan); and CK 8 (clone 35H11; Dako).
Growth inhibition curve analysis. To investigate the effects of
4-OHT on cell growth, we modified the method reported previ-
ously.(35) Both MCF-7 and BC#1 cells were incubated at vari-
ous concentrations of 4-OHT for 72 h. Cells were harvested
and viable cells were counted using the Trypan blue exclusion
method.
Statistical analysis. All results are expressed as the
means  SD from three or more independent experiments.
A statistical evaluation of the data was carried out using Stu-
dent’s t-test. P-values <0.05 were considered to be signifi-
cantly different.
We used the GraphPad Prism 6 software program (GraphPad
Software, San Diego, CA, USA) for all analyses.
Fig. 1. Characteristics of breast cancer cells. (a)
Histopathological features of derived breast cancer
tissue (magnification, 209). (b) Cell morphology of
culture cells (magnification, 49) and
immunocytochemical staining (magnification, 109).
(c) mRNA expression of estrogen receptor (ER) in
MDA-MB-231, BC#1 (black bar), MCF-7 (white bar),
and HCC1500 (gray bar) cells. The data are
presented as the means  SD from independent
measurements. P-value compared between MDA-
MB-231 (as a control) and other cell lines was
calculated using Student’s t-test. *P < 0.05. Bar
indicates 100 lm (a), 200 lm (b, except top
column), 500 lm (b, top column). CK, cytokeratin;
FOXA1, Forkhead protein; HER2, human epidermal
growth factor receptor 2; PgR, progesterone
receptor.
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Results
Characteristics of BC-derived cells. To clarify the stemness of
luminal BC, we first isolated BC cells from metastatic breast
cancer pleural effusion and characterized them. Immunohisto-
chemical staining of the surgical tissue is shown in Fig-
ure 1(a): ER-positive, HER2-negative, and FOXA1-positive
staining was evident in approximately 80–90% of cells.
NANOG, OCT4, and SOX2 were not stained in the tissue
sample (data not shown). In newly isolated cells, named
BC#1 cells, ER was not expressed, whereas PgR was
expressed in nearly 80% by immunohistochemical staining
(Fig. 1b, Table 2). As the PgR expression in the tumor has
been determined to be an indication of functional ER,(36,37)
we analyzed the expression of ER in BC#1 cells. BC#1 cells
were negative for ER according to immunohistochemical
staining, whereas ER mRNA expression was higher in BC#1
than in MDA-MB-231 cells (Fig. 1c). The reason behind the
decreased ER expression of BC#1 was surmised as follows.
It has been reported that the hormone receptor discordance
between primary and recurrent BC has occurred at the fre-
quency of 10–40%, because of the change in tumor charac-
teristics after treatment.(38) In addition, it is known that long-
term estrogen deprivation in culture causes the instability of
ER expression in vitro.(39) These factors might cause the dis-
crepancy of the ER expression in BC#1 cells isolated from
the pleural effusion. According to epithelial markers, approxi-
mately 100% of BC#1 cells were strongly positive for CK 8
and partially positive for CK 5 ⁄6. Therefore, we confirmed
that there is little contamination of the non-epithelial popula-
tion in BC#1 cells. MCF-7 and HCC1500 cells were positive
for CK 8 (Fig. 1b, Table 2). We next examined FOXA1
expression by immunohistochemical staining. FOXA1 was
positively expressed in MCF-7 and HCC1500 cells, but not
in BC#1 cells (Fig. 1b).
According to these findings, the newly isolated BC#1 cells
were categorized into the luminal type of BC cells and were
found to express different characteristics from commercially
available BC cell lines.
Table 2. Characteristics of cell lines used in this study
Cell line (ATCC name) ER PgR HER2 CK 8 CK 5 ⁄ 6
MCF7 (HTB-22) + +  + 
HCC1500 (CRL-2329) + +  + 
BC#1  +  + +
+, Positively expressed; , no expression. CK, cytokeratin; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; PgR, pro-
gesterone receptor.
Fig. 2. Assessment of the potential of cancer
stemness. (a) Aldehyde dehydrogenase (ALDH)
activity of MCF-7 (left), HCC1500 (middle), and BC#1
(right) cell lines. Black line, unstained sample;
broken line, sample treated with N,N-
diethylaminobenzaldehyde (inhibitor) and ALDH
reagent; black bold line, sample treated with ALDH
reagent. The black bar and rate shows the positive
area. (b) Morphology of MCF-7 (left), HCC1500
(middle), and BC#1 (right) cells in mammosphere
culture. Bar indicates 200 lm. (c) The number of
mammospheres greater than 100 lm in diameter in
each cell line. Black bar, HCC1500; gray bar, BC#1;
white bar, MCF-7. (d, e) ALDH activity in adherent
culture samples (d) and mammosphere culture
samples (e) of MCF-7 cells. Black line, unstained
sample; broken line, sample treated with N,N-
diethylaminobenzaldehyde and ALDH reagent;
black bold line, sample treated with ALDH reagent.
The black bar and rate shows the positive area.
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Expression of stemness markers and mammosphere forming
capacity of different luminal BC cells. We evaluated the ALDH
activity and frequency of CD44+ ⁄24 cells in our luminal BC
cell lines (Figs 2a, S1). We found that BC#1 contains CSC
populations at the highest frequency among the three BC cell
lines investigated. The number of mammospheres was the
highest in BC#1 compared to the other two BC cell lines
(Fig. 2b and 2c). It has been previously reported that the
changing of culture conditions from regular adherent culture to
mammosphere culture led to the elevated expression of genes
related to stemness.(17) As shown in Figure 2(d,e), under a
mammosphere culture, ALDH-positive MCF-7 cells increased
compared to MCF-7 cells cultured under adherent conditions.
Mammosphere culture causes ectopic expression of FOXA1 and
stemness-related genes. First, the mRNA expression of ER,
FOXA1, and stemness-related genes NANOG, SOX2, and
OCT4 were analyzed by quantitative PCR analyses.(28,40–42)
There was no significant difference in the expression of ER
between mammosphere and adhesion cultured cells. In con-
trast, the expression of FOXA1 under mammosphere culture
was significantly higher than that under adherent culture
(Fig. 3a). Similar to FOXA1 expression, stemness-related genes
were highly expressed in MCF-7 and BC#1 cell lines under
mammosphere culture compared to those under an adherent
culture. Because lower mammosphere formation was observed
in HCC1500 compared to that of MCF-7 and BC#1 cell lines,
we could not harvest sufficient samples for the analysis of
gene expression. A Western blot analysis clearly indicated that
FOXA1 protein expression was highly upregulated in both
MCF-7 and BC#1 cell lines under mammosphere culture com-
pared to adherent culture (Fig. 3b).
Ectopic FOXA1 expression in mammospheres is correlated to 4-
OHT resistance. The correlation between drug therapy resis-
tance and FOXA1 has also been reported previously.(34,43,44)
To determine the concentration of 4-OHT for BC cell resis-
tance, we examined the proliferative activity of MCF-7 and
BC#1 cell lines in the presence of various concentrations of
4-OHT. As shown in Figure 4(a), both MCF-7 and BC#1 cells
tended to maintain growth activity over 50% when 4-OHT was
added at a concentration less than 1 lM. No significant mor-
phologic changes were observed in MCF-7 or BC#1 cell lines
(data not shown). Therefore, we used 4-OHT at the concentra-
tion of 1 lM in this study. Next, we examined the effect of
4-OHT on mammosphere culture. The number of mammo-
spheres in MCF-7 and BC#1 cell lines drastically decreased in
the presence of 4-OHT (Fig. 4b,c). The expression of ER
mRNA and stemness-related genes in mammospheres from
MCF-7 and BC#1 cells did not differ according to the presence
or absence of 4-OHT. In contrast, FOXA1 mRNA expression
of 4-OHT-treated mammospheres was significantly higher than
that of the control (MCF-7, P = 0.0210; BC#1, P = 0.0353;
Fig. 4d).
Knockdown expression of FOXA1 does not correlate with
expression of stemness-related genes. To investigate the effect
of FOXA1 on the expression of stemness-related genes or mam-
mosphere forming cells, we established FOXA1 knockdown
Fig. 3. mRNA expression and Forkhead (FOXA1)
levels compared between adherent culture samples
and mammosphere culture samples. (a) mRNA
expression levels of ER, FOXA1, SOX2, OCT4, and
NANOG in each cell line are presented as the
means  SD from independent measurements.
*P < 0.05, **P < 0.01, Student’s t-test. (b) Protein
expression of FOXA1 in MCF-7 (left) and BC#1
(right) cells compared between adherent culture
and mammosphere culture by a Western blot
analysis. (c) Relative expression of FOXA1 protein
compared between cells grown in adherent culture
and mammosphere culture. The expression levels
were measured using Image J software and
presented as the means  SD from independent
measurements. *P < 0.05, **P < 0.01, Student’s t-
test.
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MCF-7 cells (shFOXA1 MCF-7 cells, Fig. 5a). These cells
showed downregulated ER and AGR2 expression, which have
been reported to be downstream of FOXA1.(45) However, the
expression of stemness-related genes, NANOG and OCT4, was
maintained at a high level compared to the control (Fig. 5b). No
significant difference in the number of mammospheres between
shFOXA1 and control cells was observed (Fig. 5c), suggesting
that FOXA1 may not affect the generation of CSCs. The colony
formation assay is widely used to evaluate the proliferative abil-
ity of immature cells.(28,46) As shown in Figure 5(d,e), the num-
ber of colonies derived from shFOXA1 MCF-7 cells
significantly decreased compared to control cells.
Taken together, these findings indicate that FOXA1 appears
to work as a factor in the proliferation rather than maintenance
of stemness-related genes or the activation of CSCs.
Discussion
Understanding the characteristics and properties of CSCs is
crucial for clinical application. Metastases and recurrence are
known to correlate with CSCs, and chemotherapeutic resis-
tance and endocrine therapy-resistance of BC are generally
known to correlate with CSC populations.(47–50) Therefore,
CSCs are the major challenge in BC treatment difficulties.
One of the methods to assess the potency of CSCs is the
mammosphere assay. Mammosphere culture was first reported
by Dontu et al.(17) to evaluate the potency of progenitor ⁄ stem
cells. A correlation has also been shown between mammo-
spheres and epithelial–mesenchymal transition(51–53) and drug
resistance.(53) Thus, we speculated that analyses of BC colo-
nies formed under the mammosphere assay would elucidate
the mechanism by which CSCs in luminal BC arise. In order
to enrich BC cells for CSC populations, mammosphere culture
was used and investigated in this study. Harrison et al.(54) pre-
viously showed that the CD44+ ⁄CD24 population generates
more mammospheres than other cell populations. Furthermore,
it has been reported that an assessment of mammospheres
could be useful to predict prognosis.(55) In this study, we deter-
mined that both established BC cell lines and commercially
established BC cell lines had CSC marker positive populations
and could form mammospheres. Each mammosphere showed
high expression of stemness-related genes, such as NANOG,
SOX2, and OCT4. Interestingly, mammosphere-forming cells
showed high expression of FOXA1 mRNA and protein com-
pared to adherent culture samples. By contrast, BC#1 cells in
adherent culture did not express FOXA1 according to immuno-
histochemical staining and Western blotting analyses. These
findings suggest that CSCs cultured under specific culture
atmospheres increase the CSC population and induce stem-
ness-related genes as well as FOXA1 expression.
Because BC is composed of various subtypes, the FOXA1
expression determined by immunohistochemical staining was
Fig. 4. Effect of 4-hydroxytamoxifen (4-OHT)
treatment on mammosphere assay. (a) Cell growth
inhibition curves with 4-OHT treatment in MCF-7
(circle) and BC#1 (square) cell lines are presented as
the means  SD. (b, c) Mammosphere numbers
greater than 100 lm in diameter in MCF-7 (b) and
BC#1 (c) cells. (d) mRNA expression levels of
mammospheres from MCF-7 and BC#1 cells in
control and 4-OHT-treated samples. Data are
presented as the means  SD from independent
measurements. *P < 0.05, **P < 0.01, Student’s
t-test.
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observed in the majority of the luminal subtype. Therefore, we
hypothesized that the prognosis of the luminal subtype regard-
ing FOXA1 expression would be superior to other types.
Indeed, a tissue analysis by immunohistochemical staining
showed that FOXA1 is a good prognosis marker of formalin-
fixed paraffin-embedded tissue staining.(33,44,56) It has also
been reported that late recurrence also tends to occur in lumi-
nal BC,(7) not in other subtypes. Some studies also show that
FOXA1 expression correlates with metastatic lesions of lumi-
nal BC.(34,57) Furthermore, Ross-Innes et al.(57) showed that
there are specific and reoccurring cis-regulatory elements that
are occupied by ER in BC; however, these vary according to
good and poor outcome samples, and FOXA1 mediates ER
reprogramming. The ectopic expression of FOXA1 observed in
our study may correlate with this mechanism.
Drug resistance is a significant problem that influences the
CSC ability. Raffo et al.(47) compared the mammosphere
formation capacity and in vivo tumorigenicity between parental
MCF-7 and 4-OHT-resistant MCF-7 cells and showed that
4-OHT-resistant MCF-7 cells had an increased mammosphere
number and tumorigenicity compared to parent MCF-7 cells.
Moreover, Calcagno et al.(48) reported that doxorubicin-resis-
tant MCF-7 cells showed high stemness potential using a
mammosphere assay, CSC markers, and tumorigenicity. Lin
et al.(58) described that tamoxifen-resistant BC cells possibly
emerge from CSC populations by validating the DNA methyla-
tion and SOX2 gene expression. In our study, the colony-form-
ing activity of 4-OHT-treated BC cells was inhibited in the
mammosphere assay. Interestingly, 4-OHT-resistant cells had
significantly increased FOXA1. Moreover, we established
shFOXA1 MCF-7 cells and investigated the relationship
between their self-renewal potential and FOXA1 expression.
As a result, the number of mammospheres was not signifi-
cantly different between shFOXA1 MCF-7 cells and control
Fig. 5. Colony formation of Forkhead (FOXA1)
knockdown MCF-7 cells. (a) Protein expression of
FOXA1 compared between control and FOXA1
knockdown cells by a Western blot analysis. (b)
mRNA expression of MCF-7 compared between
control and FOXA1 knockdown cells. Data are
presented as the means  SD from independent
measurements. *P < 0.05, **P < 0.01, Student’s t-
test. (c) Number of mammospheres greater than
100 lm in diameter in MCF-7 shControl and
shFOXA1 cells. Data are presented as the
means  SD from independent measurements. (d)
Representative photographs of colony formation.
The colonies were stained purple. (e) Comparison
of number of colonies formed between control and
FOXA1 knockdown cells. Data are presented as the
means  SD from independent measurements.
**P < 0.01, Student’s t-test.
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cells. We also observed decreased colony formation in
shFOXA1 MCF-7 cells than control cells, indicating the contri-
bution of specific culture conditions in the mammosphere
assay to activate CSCs formation.
In conclusion, our findings showed for the first time that the
CSC population in luminal BC induces ectopic expression of
FOXA1. The expression of FOXA1 appears to be involved in
the proliferation of immature BC cells rather than the induc-
tion of stemness-related genes and self-renewal potency of
CSCs.
Further studies are necessary to investigate the process of
ectopic FOXA1 expression in BC development and its biologi-
cal influence. These findings are thus expected to help estab-
lish a novel strategy to treat luminal BC and its late
recurrence.
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